Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seventh Statin Appoved: Kowa Will Take A Niche Strategy For Livalo

This article was originally published in PharmAsia News

Executive Summary

Kowa's decision to emphasize its newly approved statin Livalo'seffect in populations that are hard to treat with other statins is a wise strategy for a late entry to a class dominated by popular generics and well-established brands from marketing powerhouses like Pfizer and AstraZeneca

You may also be interested in...



Kowa Livalo Deal With Mitsubishi Tanabe Highlights Broader Expansion Plans

Mitsubishi Tanabe Pharma has agreed to market Nagoya-based drug maker Kowa's cholesterol drug Livalo (pitavastatin) through subsidiaries in Taiwan and Indonesia in a deal that shows how nimble a mid-sized Japanese firm is quickly expanding outside the home market as it gears up to enter the U.S., Canada and Europe

Kowa Livalo Deal With Mitsubishi Tanabe Highlights Broader Expansion Plans

Mitsubishi Tanabe Pharma has agreed to market Nagoya-based drug maker Kowa's cholesterol drug Livalo (pitavastatin) through subsidiaries in Taiwan and Indonesia in a deal that shows how nimble a mid-sized Japanese firm is quickly expanding outside the home market as it gears up to enter the U.S., Canada and Europe

Novartis To Seek Licensing Partner For Pitavastatin

The firm is terminating development of its lipid-lowering agent pitavastatin after disappointing Phase II trial results.

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel